AstraZeneca plc (LON:AZN)‘s stock had its “overweight” rating reissued by equities researchers at Morgan Stanley in a research report issued on Friday. They presently have a GBX 5,600 ($71.35) price objective on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential upside of 1.67% from the company’s current price.

Other analysts have also issued research reports about the company. BNP Paribas reaffirmed a “neutral” rating and issued a GBX 5,300 ($67.52) price objective on shares of AstraZeneca plc in a report on Monday, April 3rd. HSBC Holdings plc reiterated a “reduce” rating and set a GBX 4,200 ($53.51) target price on shares of AstraZeneca plc in a research report on Friday, May 5th. Shore Capital reiterated a “sell” rating on shares of AstraZeneca plc in a research report on Wednesday, May 10th. J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research report on Thursday, May 11th. Finally, Berenberg Bank boosted their price objective on AstraZeneca plc from GBX 5,670 ($72.24) to GBX 5,850 ($74.53) and gave the company a “buy” rating in a research report on Wednesday, May 17th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 5,171.80 ($65.89).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) opened at 5427.00 on Friday. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The stock’s market cap is GBX 68.71 billion. The company’s 50-day moving average price is GBX 5,134.14 and its 200-day moving average price is GBX 4,718.55.

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (AZN) Rating Reiterated by Morgan Stanley” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/23/astrazeneca-plc-azn-rating-reiterated-by-morgan-stanley.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.